

Hybridoma Development Terms and Conditions

GUARANTEES:

Package 1 and 2: ProSci Incorporated will guarantee up to three (3) ELISA positive hybridomas to the immunogen with 1×10^5 cells of each clone to either a protein antigen or a peptide antigen ProSci selected and synthesized. Because of the nature of hybridomas, and antibodies in general, it is not possible to guarantee that the clones will work for applications other than ELISA, or that a clone will work for multiple applications.

Package 1S: ProSci Incorporated will guarantee up to three (3) positive hybridomas for the screening application (western blot or immunocytochemistry) selected by the client with 1×10^5 cells of each clone.

Package 2S: ProSci Incorporated will guarantee up to three (3) ELISA positive hybridomas to the peptide antigen with 1×10^5 cells of each clone. ProSci cannot guarantee reactivity for a specific application with peptide antigens; if the first fusion does not yield clones that are positive for the screening application chosen by the client (western blot or immunocytochemistry), a second fusion will be performed at no charge. ProSci can terminate the project if the second fusion is not successful in yielding clones for the selected screening application and will not invoice phase III or will refund phase III if paid and client will only pay for peptide synthesis, conjugation, immunization, and one fusion.

Researcher Screening of Positive Wells: In order to improve the chances of obtaining antibodies suitable to your needs, clients have the option of screening the cultured supernatants from up to 100 positive wells following fusion. If this option is ordered, client results must be forwarded to ProSci within 7 days of shipping of the supernatant samples. After this time a non-refundable per diem maintenance fee will be charged to your account. Because of the time critical nature of cloning, selections received after the 7 day period will void any expressed or implied guarantees. Please note ProSci cannot guarantee the continued reactivity seen in supernatants throughout sub-cloning.

ADDITIONAL INFORMATION:

Antibodies that work well in one application may not work in another. We can, however, guarantee that each clone will recognize the immunogen in ELISA as this is our primary method of screening. The success of a project is dependent upon the immunogen, screening methods for hybridomas, etc. We highly recommend screening positive wells, especially if a peptide immunogen is used as this will increase the chances of developing a cell line that produces monoclonal antibodies that work in your target application. Additional positive clones may be available at additional cost.

We cannot guarantee the success of a project where the customer provides the antigen; however it is our experience that monoclonal projects using a recombinant protein yield monoclonal antibodies that have a higher recognition rate to the native protein than by using a peptide immunogen. The customer must also be aware that a customer-provided immunogen may not yield the immune response required for fusion. If the customer provides the immunogen there will not be a refund for phase one if there is insufficient titer for fusion following the 6th test-bleed in the immunization protocol.

If there is a successful fusion with no resulting ELISA-positive clones, phase one will *not* be refunded, although we will perform a second fusion at no charge. If the customer is not satisfied with the positive wells at screening or final clones they may opt to pay for another round of fusion and/or sub-cloning at additional cost.